Treating Patients with Complex Metabolic Conditions


Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral protein therapeutics to patients with serious renal, urologic, and orphan diseases. Allena is currently conducting a Phase 2 program for its lead product candidate, ALLN-177, in patients with hyperoxaluria. The company’s technological approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by degrading toxic metabolites, without being absorbed into the bloodstream.


Year Invested: 2011
Location: Newton, Mass.
Visit: www.allenapharma.com

Recent News

November 1, 2017
Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

July 27, 2017
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals' Investigational Therapy for the Treatment of Primary Hyperoxaluria

July 13, 2017
FDA Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner